Endothelial dysfunction in multiple sclerosis and management options using alpha-lipoic acid
https://doi.org/10.21518/2079-701X-2015-18-68-73
Abstract
81 patients with definite diagnosis of multiple sclerosis (MS) according to McDonald et all. criteria underwent a comprehensive clinical and neurological examination in 2005 and 2010, and their blood serum was measured for the amount of matrix metalloproteinase-9 (MMP9) and von Willebrand factor antigen (vWf) using ELISA. Von Willebrand factor antigen levels were definitely significantly lower in the group of patients treated with alpha-lipoic acid at the time of the study compared with the group without concomitant ALA therapy. There were no significant differences between the groups of patients by the level of MMP9 in this study. ALA therapy for multiple sclerosis has positive effects associated also with a decrease in cerebral vascular endothelial damage, thus making it pathogenetically substantiated.
About the Authors
N. N. Spirina
Yaroslavl State Medical University
Russian Federation
Russian Federation
N. N. Spirin
Yaroslavl State Medical University
Russian Federation
Russian Federation
A. N. Boyko
Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
References
1. Спирина Н.Н., Спирин Н.Н., Фадеева О.А., Шипова Е.Г., Бойко А.Н. Рассеянный склероз и эндотелиальная дисфункция (обзор). Журнал неврологии и психиатрии им. C.C. Корсакова. 2013. 113, 10-2: 32-42.
2. Переседова А.В., Куликова С.Н., Завалишин И.А. Сосудистый фактор при рассеянном склерозе: миф или реальность? Анналы клинической и экспериментальной неврологии. 2013. 7, 3: 55-59.
3. Adams CWM, Poston RN, Buk SJ et al. Inflammatory vasculitis in multiple sclerosis. J. Neurol. Sci. 1985. 69: 269-283.
4. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1988. 51 (2): 260-265.
5. Washington R, Burton J, Todd RF, Newman W, Dragovic L et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microves-sels from patients with multiple sclerosis. Ann. Neurol. 1994. 35(1): 89-97.
6. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J. Cereb. Blood. Flow. Metab. 2012. 32(7): 1207-1221.
7. Canella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995. 37(4): 424-435.
8. Ingrisch M, Sourbron S, Morhard D, Ertl-Wagner B, Kumpfel T et al. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest. Radiol. 2012. 47(4): 252-258.
9. Wakefied AJ, More LJ, Difford J, McLaughlin JE. Immunohistochemical study of vascular injury in acute multiple sclerosis. J. Clin. Pathol. 1994. 47(2): 129-133.
10. Павлов А.Ю., Бисага Г.Н., Декан В.С., Рудь С.Д., Гайкова О.Н., Онищенко Л.С. Изменения вну-тримозговых сосудов и регионального мозгового кровотока при рассеянном склерозе. Вест. Росс. Воен-мед. акад. 2008. 4: 66-72.
11. Mancini M, Morra VB, Di Donato O, Maglio V Lanzillo R et al. Multiple sclerosis: cerebral circulation time. Radiology. 2012. 262(3): 947-955.
12. Ge Y, Law M, Johnson G, Herbert J, Babb JS et al. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am. J. Neuroradiol. 2005. 26(6): 1539-1547.
13. Inglese M, Park S, Johnson G, Babb JS, Miles L et al. Deep Gray Matter Perfusion in Multiple Sclerosis: Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging at 3 T. Arch. Neurol. 2007. 64(2): 196-202.
14. Гусев Е.И., Бойко А.Н., Кольяк Е.В., Камчатнов П.Р., Каралкин А.В., Мартынов М.Ю. Вклад нарушений микроциркуляции в формирование клинической картины рассеянного склероза в возрасте после 45 лет и возможные направления коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008. 5: 84-94.
15. Karmon Y, Ramanathan M, Minagar A, Zivadinov R, Weinstock-Guttman B. Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol. Res. 2012. 34(8): 754-760.
16. Спирина Н.Н., Спирин Н.Н., Бойко А.Н. Фактор Фон Виллебранда и молекулы адгезии у пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2014. 114, 2-2: 35-39.
17. Спирина Н.Н., Спирин Н.Н., Бойко А.Н. Эндотелиальная дисфункция у пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2014. 114: 433-434.
18. Спирина Н.Н., Спирин Н.Н., Бойко А.Н. Влияние патогенетической терапии на эндо-телиальную дисфункцию при РС. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015. 115, 8-2: 84.
19. Пухов Р.В., Бисага Г.Н., Труфанов А.Г, Ефимцев А.Ю., Фокин В.А. Влияние нейротрофической терапии на метаболизм головного мозга при рассеянном склерозе. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013. 113, 10-2: 97-104.
20. Бисага Г.Н., Одинак М.М., Бойко А.Н., Мельник Ю.Б., Попова Н.Ф. Возможности лечения обострений рассеянного склероза без применения кортикостероидов: роль метаболической и антиоксидантной терапии. Журнал неврологии и психиатрии им. C.C. Корсакова. 2011. 111, 2: 44-48.
21. Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets. 2008. 8(2): 132-42.
22. Khalili M, Eghtesadi S, Mirshafiey A, Eskandari G, Sanoobar M et al. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial. Nutr Neurosci. 2014. 17(1): 16-20.
23. Воробьева О.В. Тиоктовая (альфа-липоевая) кислота - спектр клинического применения. Журнал неврологии и психиатрии им. C.C. Корсакова. 2011. 111, 10: 86-90.
24. Chaudhary P, Marracci G, Yu X, Galipeau D, Morris B et al. Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol. 2011. 233(1-2): 90-6.
25. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004. 148(1-2): 146-153.
26. Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002. 131(1-2): 104-114.
27. Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK et al. Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res. 2004. 78(3): 362-370.
28. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK et al. Alpha-lipoic acid inhibits matrix metallopro-teinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med. 2007. 39(1): 106-113.
29. Kohriyama T, Maruyama H, Kurokawa K, Harada T, Nakamura S. Endothelial cell activation and/ or injury in multiple sclerosis: analysis with von Willebrand factor and thrombomodulin. Rinsho Shinkeigaku. 1997. 37(4): 287-291.
30. Noubade R, del Rio R, McElvany B, Zachary JF, Millward JM et al. von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encepha-lomyelitis. Am J Pathol. 2008. 173(3): 892-900.
31. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005. 11(2): 159-165.
32. Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014. 21(6): 291-296.
Review
For citations:
Spirina NN, Spirin NN, Boyko AN. Endothelial dysfunction in multiple sclerosis and management options using alpha-lipoic acid. Meditsinskiy sovet = Medical Council. 2015;(18):68-73. (In Russ.) https://doi.org/10.21518/2079-701X-2015-18-68-73
Views:
1341
Email this article 